Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.
Ochoa-Azze R, Chang-Monteagudo A, Climent-Ruiz Y, Macías-Abraham C, Valenzuela-Silva C, de Los Ángeles García-García M, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Dairon Rodríguez-Prieto L, Guerra-Chaviano PP, Sánchez-Ramírez B, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, Chiodo F, Calcagno A, Ghisetti V, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Ortega-León D, Valdivia-Álvarez I, Delahanty-Fernández A, Palenzuela-Díaz A, Rodríguez-Noda L, González-Mugica R, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Ochoa-Azze R, et al. Among authors: palenzuela diaz a. Lancet Respir Med. 2022 Aug;10(8):785-795. doi: 10.1016/S2213-2600(22)00100-X. Epub 2022 Jun 9. Lancet Respir Med. 2022. PMID: 35691295 Free PMC article. Clinical Trial.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Eugenia-Toledo-Romaní M, Verdecia-Sánchez L, Rodríguez-González M, Rodríguez-Noda L, Valenzuela-Silva C, Paredes-Moreno B, Sánchez-Ramírez B, Pérez-Nicado R, González-Mugica R, Hernández-García T, Bergado-Baez G, Pi-Estopiñán F, Cruz-Sui O, Fraga-Quintero A, García-Montero M, Palenzuela-Díaz A, Baró-Román G, Mendoza-Hernández I, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, Ramírez Gonzalez U, García-Vega Y, Pérez-Massón B, Guang-Wu-Chen, Boggiano-Ayo T, Ojito-Magaz E, Rivera DG, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group; Gómez-Maceo Y, Reyes-Matienzo R, Manuel Coviella-Artime J, Morffi-Cinta I, Martínez-Pérez M, Castillo-Quintana I, Garcés-Hechavarría A, Valera-Fernández R, Martínez-Bedoya D, Garrido-Arteaga R, Cardoso-SanJorge F, Quintero Moreno L, Ontivero-Pino I, Teresa Pérez-Guevara M, Morales-García M, Noa-Romero E, Orosa-Vázquez I, Díaz-Hernández M, Rojas G, Tundidor Y, García-López E, Muñoz-Morejon Y, Galano-Frutos E, Rodríguez-Alvarez J, Arteaga A, Medina Nápoles M, Espi Ávila J, Fontanies Fernández M. Eugenia-Toledo-Romaní M, et al. Among authors: palenzuela diaz a. Vaccine. 2022 Jul 29;40(31):4220-4230. doi: 10.1016/j.vaccine.2022.05.082. Epub 2022 Jun 6. Vaccine. 2022. PMID: 35691871 Free PMC article. Clinical Trial.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Toledo-Romani ME, García-Carmenate M, Verdecia-Sánchez L, Pérez-Rodríguez S, Rodriguez-González M, Valenzuela-Silva C, Paredes-Moreno B, Sanchez-Ramirez B, González-Mugica R, Hernández-Garcia T, Orosa-Vázquez I, Díaz-Hernández M, Pérez-Guevara MT, Enriquez-Puertas J, Noa-Romero E, Palenzuela-Diaz A, Baro-Roman G, Mendoza-Hernández I, Muñoz Y, Gómez-Maceo Y, Santos-Vega BL, Fernandez-Castillo S, Climent-Ruiz Y, Rodríguez-Noda L, Santana-Mederos D, García-Vega Y, Chen GW, Doroud D, Biglari A, Boggiano-Ayo T, Valdés-Balbín Y, Rivera DG, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group. Toledo-Romani ME, et al. Among authors: palenzuela diaz a. Med. 2022 Nov 11;3(11):760-773.e5. doi: 10.1016/j.medj.2022.08.001. Epub 2022 Aug 8. Med. 2022. PMID: 35998623 Free PMC article. Clinical Trial.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, Pérez NP, Paredes-Moreno B, Rodríguez-González M, Valenzuela-Silva C, Sánchez-Ramírez B, Rodríguez-Noda L, Pérez-Nicado R, González-Mugica R, Hernández-García T, Fundora-Barrios T, Echevarría MD, Enriquez-Puertas JM, Infante-Hernández Y, Palenzuela-Díaz A, Gato-Orozco E, Chappi-Estévez Y, Francisco-Pérez JC, Suarez-Martinez M, Castillo-Quintana IC, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, García-Vega Y, Toledo-Romani ME, Doroud D, Biglari A, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group. Puga-Gómez R, et al. Among authors: palenzuela diaz a. Int J Infect Dis. 2023 Jan;126:164-173. doi: 10.1016/j.ijid.2022.11.016. Epub 2022 Nov 18. Int J Infect Dis. 2023. PMID: 36403819 Free PMC article. Clinical Trial.
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, Urrutia-Pérez K, Urrutia-Pérez K, Chávez-Chong CO, Azor-Hernández JL, Rodríguez-Reinoso JL, Lobaina-Lambert L, Colina-Ávila E, Bizet-Almeida J, Rodríguez-Nuviola J, Del Valle-Piñera S, Ramírez-Domínguez M, Tablada-Ferreiro E, Alonso-Valdés M, Lemos-Pérez G, Guillén-Nieto GE, Palenzuela-Díaz A, Noa-Romero E, Limonta-Fernández M, Fernández-Ávila JM, Ali-Mros NA, Del Toro-Lahera L, Remedios-Reyes R, Ayala-Ávila M, Muzio-González VL. Hernández-Bernal F, et al. Among authors: palenzuela diaz a. EClinicalMedicine. 2022 Apr;46:101383. doi: 10.1016/j.eclinm.2022.101383. Epub 2022 Apr 9. EClinicalMedicine. 2022. PMID: 35434578 Free PMC article.